Cargando…
Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases
In epithelial ovarian cancer (EOC), the strongest prognostic factor is the completeness of surgery. Intraoperative molecular imaging that targets cell-surface proteins on tumor cells may guide surgeons to detect metastases otherwise not visible to the naked eye. Previously, we identified 29% more me...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352913/ https://www.ncbi.nlm.nih.gov/pubmed/32545676 http://dx.doi.org/10.3390/cancers12061562 |
_version_ | 1783557750586867712 |
---|---|
author | de Muynck, Lysanne D. A. N. Gaarenstroom, Katja N. Sier, Cornelis F. M. van Duijvenvoorde, Maurice Bosse, Tjalling Mieog, J. Sven D. de Kroon, Cornelis D. Vahrmeijer, Alexander L. Peters, Inge T. A. |
author_facet | de Muynck, Lysanne D. A. N. Gaarenstroom, Katja N. Sier, Cornelis F. M. van Duijvenvoorde, Maurice Bosse, Tjalling Mieog, J. Sven D. de Kroon, Cornelis D. Vahrmeijer, Alexander L. Peters, Inge T. A. |
author_sort | de Muynck, Lysanne D. A. N. |
collection | PubMed |
description | In epithelial ovarian cancer (EOC), the strongest prognostic factor is the completeness of surgery. Intraoperative molecular imaging that targets cell-surface proteins on tumor cells may guide surgeons to detect metastases otherwise not visible to the naked eye. Previously, we identified 29% more metastatic lesions during cytoreductive surgery using OTL-38, a fluorescent tracer targeting folate receptor-α (FRα). Unfortunately, eleven out of thirteen fluorescent lymph nodes were tumor negative. The current study evaluates the suitability of five biomarkers (EGFR, VEGF-A, L1CAM, integrin αvβ6 and EpCAM) as alternative targets for molecular imaging of EOC metastases and included FRα as a reference. Immunohistochemistry was performed on paraffin-embedded tissue sections of primary ovarian tumors, omental, peritoneal and lymph node metastases from 84 EOC patients. Tumor-negative tissue specimens from these patients were included as controls. EGFR, VEGF-A and L1CAM were highly expressed in tumor-negative tissue, whereas αvβ6 showed heterogeneous expression in metastases. The expression of EpCAM was most comparable to FRα in metastatic lesions and completely absent in the lymph nodes that were false-positively illuminated with OTL-38 in our previous study. Hence, EpCAM seems to be a promising novel target for intraoperative imaging and may contribute to a more reliable detection of true metastatic EOC lesions. |
format | Online Article Text |
id | pubmed-7352913 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73529132020-07-15 Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases de Muynck, Lysanne D. A. N. Gaarenstroom, Katja N. Sier, Cornelis F. M. van Duijvenvoorde, Maurice Bosse, Tjalling Mieog, J. Sven D. de Kroon, Cornelis D. Vahrmeijer, Alexander L. Peters, Inge T. A. Cancers (Basel) Article In epithelial ovarian cancer (EOC), the strongest prognostic factor is the completeness of surgery. Intraoperative molecular imaging that targets cell-surface proteins on tumor cells may guide surgeons to detect metastases otherwise not visible to the naked eye. Previously, we identified 29% more metastatic lesions during cytoreductive surgery using OTL-38, a fluorescent tracer targeting folate receptor-α (FRα). Unfortunately, eleven out of thirteen fluorescent lymph nodes were tumor negative. The current study evaluates the suitability of five biomarkers (EGFR, VEGF-A, L1CAM, integrin αvβ6 and EpCAM) as alternative targets for molecular imaging of EOC metastases and included FRα as a reference. Immunohistochemistry was performed on paraffin-embedded tissue sections of primary ovarian tumors, omental, peritoneal and lymph node metastases from 84 EOC patients. Tumor-negative tissue specimens from these patients were included as controls. EGFR, VEGF-A and L1CAM were highly expressed in tumor-negative tissue, whereas αvβ6 showed heterogeneous expression in metastases. The expression of EpCAM was most comparable to FRα in metastatic lesions and completely absent in the lymph nodes that were false-positively illuminated with OTL-38 in our previous study. Hence, EpCAM seems to be a promising novel target for intraoperative imaging and may contribute to a more reliable detection of true metastatic EOC lesions. MDPI 2020-06-12 /pmc/articles/PMC7352913/ /pubmed/32545676 http://dx.doi.org/10.3390/cancers12061562 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article de Muynck, Lysanne D. A. N. Gaarenstroom, Katja N. Sier, Cornelis F. M. van Duijvenvoorde, Maurice Bosse, Tjalling Mieog, J. Sven D. de Kroon, Cornelis D. Vahrmeijer, Alexander L. Peters, Inge T. A. Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases |
title | Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases |
title_full | Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases |
title_fullStr | Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases |
title_full_unstemmed | Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases |
title_short | Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases |
title_sort | novel molecular targets for tumor-specific imaging of epithelial ovarian cancer metastases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352913/ https://www.ncbi.nlm.nih.gov/pubmed/32545676 http://dx.doi.org/10.3390/cancers12061562 |
work_keys_str_mv | AT demuyncklysannedan novelmoleculartargetsfortumorspecificimagingofepithelialovariancancermetastases AT gaarenstroomkatjan novelmoleculartargetsfortumorspecificimagingofepithelialovariancancermetastases AT siercornelisfm novelmoleculartargetsfortumorspecificimagingofepithelialovariancancermetastases AT vanduijvenvoordemaurice novelmoleculartargetsfortumorspecificimagingofepithelialovariancancermetastases AT bossetjalling novelmoleculartargetsfortumorspecificimagingofepithelialovariancancermetastases AT mieogjsvend novelmoleculartargetsfortumorspecificimagingofepithelialovariancancermetastases AT dekrooncornelisd novelmoleculartargetsfortumorspecificimagingofepithelialovariancancermetastases AT vahrmeijeralexanderl novelmoleculartargetsfortumorspecificimagingofepithelialovariancancermetastases AT petersingeta novelmoleculartargetsfortumorspecificimagingofepithelialovariancancermetastases |